AtriCure (NASDAQ:ATRC) Issues Quarterly Earnings Results

AtriCure (NASDAQ:ATRC) posted its quarterly earnings data on Tuesday. The medical device company reported $0.00 EPS for the quarter, beating the consensus estimate of ($0.07) by $0.07, reports. The firm had revenue of $141.25 million during the quarter, compared to analyst estimates of $139.75 million. AtriCure had a negative net margin of 0.83% and a positive return on equity of 0.29%. The company’s revenue for the quarter was up 14.3% on a year-over-year basis. During the same quarter last year, the business posted ($0.14) EPS. AtriCure updated its FY 2026 guidance to 0.000-0.040 EPS.

Here are the key takeaways from AtriCure’s conference call:

• Q1 worldwide revenue of $141.2 million (up ~14% YoY) drove a near-doubling of adjusted EBITDA to $17.1 million and a breakeven net income, with gross margin improving to 77.4% (+246 bps).
• The BoxX-NoAF randomized trial is enrolling ~300 of 960 patients and is tracking ~1 year ahead of plan, with full enrollment expected around the end of 2026 — a catalytic data event that could materially expand the addressable market for postoperative AFib prevention.
• Product momentum is driving growth — pain management (cryoSPHERE MAX) grew ~28% and contributed ~70% of pain sales, while open ablation (EnCompass Clamp) and appendage management (AtriClip FLEX‑Mini, which represented ~40% of U.S. open appendage revenue) continue to gain adoption.
• Management reiterated full‑year guidance of $600–$610 million revenue and $80–$82 million adjusted EBITDA, but accelerated BoxX-NoAF enrollment will raise R&D spending over the next three quarters (company expects to absorb the incremental cost).
• Headwinds remain in minimally invasive (MIS) ablation — U.S. MIS sales fell ~25% YoY — and international growth is uneven (11.5% reported, 3.3% constant currency) due to U.K. uncertainty and lumpy APAC distributor orders.

AtriCure Stock Performance

ATRC traded down $0.21 on Thursday, hitting $27.80. The company’s stock had a trading volume of 1,005,702 shares, compared to its average volume of 868,061. The company’s 50 day simple moving average is $29.24 and its 200-day simple moving average is $34.28. The firm has a market cap of $1.41 billion, a P/E ratio of -278.00 and a beta of 1.28. AtriCure has a 12 month low of $26.62 and a 12 month high of $43.18. The company has a quick ratio of 2.99, a current ratio of 3.96 and a debt-to-equity ratio of 0.13.

Insider Buying and Selling

In related news, insider Vinayak Doraiswamy sold 5,000 shares of the firm’s stock in a transaction that occurred on Thursday, March 12th. The shares were sold at an average price of $29.83, for a total value of $149,150.00. Following the completion of the transaction, the insider directly owned 96,875 shares of the company’s stock, valued at approximately $2,889,781.25. This trade represents a 4.91% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Company insiders own 4.00% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the business. Captrust Financial Advisors boosted its holdings in AtriCure by 7.9% in the 4th quarter. Captrust Financial Advisors now owns 7,944 shares of the medical device company’s stock worth $314,000 after buying an additional 579 shares during the period. Osaic Holdings Inc. boosted its holdings in AtriCure by 195.6% in the 4th quarter. Osaic Holdings Inc. now owns 7,184 shares of the medical device company’s stock worth $284,000 after buying an additional 4,754 shares during the period. Arete Wealth Advisors LLC bought a new position in AtriCure in the 4th quarter worth approximately $222,000. Prudential Financial Inc. bought a new position in AtriCure in the 2nd quarter worth approximately $215,000. Finally, Brooklyn Investment Group bought a new position in AtriCure in the 4th quarter valued at $202,000. 99.11% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

Several research firms have commented on ATRC. JPMorgan Chase & Co. lowered shares of AtriCure from an “overweight” rating to a “neutral” rating and set a $36.00 price objective for the company. in a research note on Wednesday, February 11th. Citizens Jmp decreased their price target on shares of AtriCure from $60.00 to $52.00 and set a “market outperform” rating for the company in a research note on Wednesday, February 18th. Zacks Research lowered shares of AtriCure from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, February 18th. Needham & Company LLC restated a “buy” rating and set a $45.00 price target on shares of AtriCure in a research note on Thursday, February 12th. Finally, Citigroup restated an “outperform” rating on shares of AtriCure in a research note on Wednesday, February 18th. One investment analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, AtriCure presently has a consensus rating of “Moderate Buy” and a consensus target price of $48.71.

AtriCure Company Profile

AtriCure, Inc is a medical device company focused on the development, manufacture and marketing of innovative therapies to treat atrial fibrillation (AF) and related conditions. Founded in 2000 and headquartered in Mason, Ohio, AtriCure has established itself as a leader in surgical ablation devices designed to interrupt the errant electrical pathways that cause AF. The company’s solutions are used by cardiac surgeons and electrophysiologists to reduce the risk of stroke and improve patient outcomes in the treatment of both paroxysmal and persistent AF.

The company’s product portfolio centers on its Synergy Surgical Ablation System, which delivers controlled radiofrequency energy in a minimally invasive format, and the cryoICE Cryoablation System, which offers an alternative ablation modality using precise freezing techniques.